Research and Development
We are advancing alicaforsen for the treatment of GI diseases. In addition renzapride offers the potential for clinical treatment of GI dysmotility.
Alicaforsen is a novel antisense oligonucleotide targeted to down regulate the production of ICAM-1, a cell surface receptor which is involved in the process of inflammation.
Renzapride is considered best in class orally bioavailable small molecule with a dual mode of action which can increase gut motility and reduce nausea and vomiting.
